Product logins

Find logins to all Clarivate products below.


Gout | Treatment Algorithms | Claims Data Analysis | US | 2021

MARKET OUTLOOK

Gout is a chronic arthritic condition caused by elevated serum uric acid (sUA) characterized by intermittent acute flares. Treatment of the painful acute flares is distinct from the chronic management of hyperuricemia with urate-lowering therapies and is not considered in this study. The aim of chronic treatment is to reduce the number and severity of acute flares and damage to the affected joints. Xanthine oxidase inhibitors (XOIs) are the mainstay of chronic gout treatment, with generic allopurinol prescribed extensively. Krystexxa is a highly efficacious biologic drug reserved for later lines of therapy.

QUESTIONS ANSWERED

  • What patient shares do key therapies and brands garner by line oftherapy in newly diagnosed gout patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed gout patients?
  • How has Krystexxa been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of gout patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of gout patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

CONTENT HIGHLIGHTS

  • Markets covered: United States
  • Key companies: Horizon Pharma, Takeda Pharmaceuticals, Cardinal Health
  • Key drugs: Krystexxa, febuxostat, allopurinol, probenecid, probenecid / colchicine

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Related Market Assessment Reports

Report
Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)
Gout, a form of inflammatory arthritis, arises due to the persistent elevation of serum uric acid (sUA) levels. The condition manifests through sudden and intense gout flares, causing significant…
Report
Scleroderma (Systemic Sclerosis) – Current Treatment – Treatment Algorithms: Claims Data Analysis – Scleroderma (Systemic Sclerosis) (US)
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Report
Alopecia – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alopecia Areata (US)
Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. Topical…
Report
Hypertrophic Cardiomyopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hypertrophic Cardiomyopathy (US)
HCM is a genetic heart condition characterized by thickened myocardium and left ventricular hypertrophy, often linked to sarcomere mutations. While some patients remain asymptomatic, common…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Geographic Focus: China – Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – China In-Depth (China)
The NHL therapy market in China is poised for significant growth over the next decade, driven by the introduction of novel therapies and the continued uptake and label expansion of premium-priced…